You are here: Industry Insights > schizophrenia

News List

New insight into genetic schizophrenia risk expresspharma
April 28, 2020
For the first time, research reported by the team in the journal Cell Reports, has shown that the 16p11.2 duplication impacts on a number of different inhibitory neuron types, neurons that use the neurotransmitter GABA, in brain areas dysfunctional in sch
Intra-Cellular Therapies Announces Availability of CAPLYTA for Schizophrenia americanpharmaceuticalreview
March 27, 2020
Intra-Cellular Therapies announced CAPLYTA (lumateperone) is now available to pharmacies in the U.S. CAPLYTA is an oral, once daily medicine approved for the treatment of schizophrenia in adults.
Cadent Therapeutics Announces FDA Clearance of IND Application for Schizophrenia Treatment americanpharmaceuticalreview
March 11, 2020
Cadent Therapeutics announced the U.S. Food and Drug Administration (FDA) has provided clearance to proceed for its Investigational New Drug (IND) application for its lead cognitive disorder asset, CAD-9303, a novel, first-in-class ...
Antipsychotic Use Safer Than No Use in Schizophrenia drugs
January 20, 2020
Among patients with schizophrenia, long-term antipsychotic use does not appear to increase severe physical morbidity or somatic hospitalization, and mortality is lower for antipsychotic use compared with no use ...
BioMed X Starts New Schizophrenia Research Program with Boehringer Ingelheim b3cnewswire
January 16, 2020
BioMed X announced the start of a new joint research group in collaboration with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg.
OWP Announces Pre-IND Acknowledgement, Patent Application for Schizophrenia, Bipolar Disorder Treatment americanpharmaceuticalreview
January 13, 2020
OWP Pharmaceuticals has received Pre-Investigational New Drug (PIND) acknowledgement from the U.S. Food and Drug Administration (FDA), and has submitted for U.S. patent protection, for the first-ever liquid formulation of quetiapine fumarate.
Could the Family Dog Lower a Child's Odds for Schizophrenia Later? drugs
January 02, 2020
You might just want to throw Fido a few extra bones for the holidays, as new research suggests that growing up with a dog may lower schizophrenia risk by as much as 24%.
FDA Approves Schizophrenia Treatment americanpharmaceuticalreview
December 24, 2019
Intra-Cellular Therapies announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults.
Schizophrenia Clinical Research Receives NIMH Funding americanpharmaceuticalreview
September 23, 2019
Feinstein Institutes for Medical Research scientists have been awarded a five-year, $7.3 million National Institutes of Mental Health (NIMH) grant to support their research in improved schizophrenia treatment.
Sodium benzoate enhances schizophrenia treatment europeanpharmaceuticalreview
April 29, 2019
A randomised, double-blind, placebo-controlled trial has found that sodium benzoate improves symptoms in clozapine-resistant schizophrenia…

Previous page 1 2 3 4 5 Next page